SCHEMBL20176007

SCHEMBL20176007

Nc1cc(/C=C/c2ccccc2)cc2cc(/C=C/c3ccccc3)cnc12

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.56
PDGFRA P16234 2/20 0.56
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GRM4 Q14833 7/20 0.43
HDAC6 Q9UBN7 1/20 0.42
CYP19A1 P11511 2/20 0.42
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
RELA Q04206 1/20 0.42
GRM5 P41594 1/20 0.41
IP6K1 Q92551 1/20 0.39
RAB9A P51151 1/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20176006 0.85 PDGFRB (0.58) PDGFRBPDGFRAKDM4EALDH1A1HPGD
SCHEMBL20176010 0.84 PTGS1 (0.41) PDGFRBPDGFRAMEN1KMT2AGRM4
SCHEMBL25181914 0.72 PDGFRB (0.46) PDGFRBPDGFRAKDM4EALDH1A1HPGD
SCHEMBL1056354 0.72 PDGFRB (0.54) PDGFRBPDGFRAKDM4EALDH1A1HPGD
SCHEMBL1056355 0.72 PDGFRB (0.54) PDGFRBPDGFRAKDM4EALDH1A1HPGD
SCHEMBL28155704 0.72 CYP19A1 (0.56) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL3164863 0.72 PDGFRB (1.00) PDGFRBPDGFRAKDM4EALDH1A1HPGD
SCHEMBL3164867 0.72 PDGFRB (1.00) PDGFRBPDGFRAKDM4EALDH1A1HPGD
SCHEMBL3927482 0.67 MAOB (0.56) PDGFRBPDGFRAKDM4EALDH1A1HPGD
SCHEMBL3927479 0.67 MAOB (0.56) PDGFRBPDGFRAKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141911-A1 Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease NORTHEASTERN UNIVERSITY 2018-05-24 US disclosed
US-20180141911-A1 Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease NORTHEASTERN UNIVERSITY 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141911-A1 Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease MAPT, PSEN1, PSEN2 PDGFRB 4510/4885PDGFRA 4413/4885KDM4E 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.